The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.

[1]  E. Rosenqvist,et al.  Immune Responses against Major Outer Membrane Antigens of Neisseria meningitidis in Vaccinees and Controls Who Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trial , 1998, Infection and Immunity.

[2]  B. Plikaytis,et al.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. , 1998, The Journal of infectious diseases.

[3]  E. Rosenqvist,et al.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine , 1995, Infection and immunity.

[4]  M. Sarvas,et al.  The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. , 1995, Vaccine.

[5]  T. Michaelsen,et al.  Opsonophagocytic Activity Induced by Chimeric Antibodies of the Four Human IgG Subclasses With or Without Help from Complement , 1994, Scandinavian journal of immunology.

[6]  G. Sierra,et al.  Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B. , 1994, Archives of medical research.

[7]  M. Sarvas,et al.  The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity , 1992, Molecular microbiology.

[8]  S. Funnell,et al.  Intranasal infection of infant mice with Neisseria meningitidis. , 1992, Microbial pathogenesis.

[9]  T. Hervig,et al.  Monocyte phagocytosis of opsonized Neisseria meningitidis serogroup B , 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[11]  E. Rosenqvist,et al.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. , 1991, NIPH annals.

[12]  E. Rosenqvist,et al.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. , 1991, NIPH annals.

[13]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[14]  A. Barlow,et al.  Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity , 1990, The Journal of experimental medicine.

[15]  H. Smith,et al.  Pathogenicity and the microbe in vivo. The 1989 Fred Griffith Review Lecture. , 1990, Journal of general microbiology.

[16]  J. Poolman,et al.  Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. , 1989, Vaccine.

[17]  E. Tarkka,et al.  Sero- and subtypes of group B meningococci causing invasive infections in Finland in 1976-87. , 1989, Scandinavian journal of infectious diseases.

[18]  L. Frøholm,et al.  Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. , 1988, Journal of immunological methods.

[19]  K. Saukkonen.  Experimental meningococcal meningitis in the infant rat. , 1988, Microbial pathogenesis.

[20]  M. Leinonen,et al.  Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. , 1987, Microbial pathogenesis.

[21]  P. Rosenthal,et al.  Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. , 1987, The Journal of infectious diseases.

[22]  H. Zanen,et al.  MENINGOCOCCAL SEROTYPES AND SEROGROUP B DISEASE IN NORTH-WEST EUROPE , 1986, The Lancet.

[23]  L. Frøholm,et al.  Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting , 1986, Infection and immunity.

[24]  F. Ashton,et al.  Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody , 1985, Infection and immunity.

[25]  K. Timmis,et al.  NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Van Melle,et al.  Experimental meningococcal infection in neonatal animals: models for mucosal invasiveness. , 1984, Canadian journal of microbiology.

[27]  H. Peltola.  Meningococcal disease: still with us. , 1983, Reviews of infectious diseases.

[28]  Madeleine Huet,et al.  Un modèle animal pour l'activité des vaccins polyosidiques méningococciques , 1981 .

[29]  B. Holbein,et al.  Neisseria meningitidis infection in mice: influence of iron, variations in virulence among strains, and pathology , 1979, Infection and immunity.

[30]  W. Wilhelmsen,et al.  Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978 , 1979, Journal of clinical microbiology.

[31]  C. Frasch,et al.  Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model , 1976, The Journal of experimental medicine.

[32]  P. Mäkelä,et al.  EFFECT OF GROUP-A MENINGOCOCCAL VACCINE IN ARMY RECRUITS IN FINLAND , 1975, The Lancet.

[33]  E. Moxon,et al.  Production of Haemophilus influenzae b Meningitis in Infant Rats by Intraperitoneal Inoculation , 1973, Infection and immunity.

[34]  E. Gotschlich,et al.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. , 1973, Bulletin of the World Health Organization.

[35]  D. Kasper,et al.  Immunologic response of man to group B meningococcal polysaccharide vaccines. , 1972, The Journal of infectious diseases.

[36]  J. Conte.  The clinical spectrum of meningococcal disease. , 1970, California medicine.

[37]  R. Roberts.  THE RELATIONSHIP BETWEEN GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDES AND SERUM OPSONINS IN MAN , 1970, The Journal of experimental medicine.

[38]  M. Artenstein,et al.  Prevention of meningococcal disease by group C polysaccharide vaccine. , 1970, The New England journal of medicine.

[39]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[40]  Miller Cp.  EXPERIMENTAL MENINGOCOCCAL INFECTION IN MICE. , 1933 .